What it sells
Elevated mRNA for transformative medicines.
Business model breakdown
Workflow: what inputs become what output?
Proprietary APEXm mRNA platform with RNA domains that recruit native stabilizing machinery for higher, longer protein expression; lead program is in vivo CAR-T for autoimmune disease, then oncology and therapeutic proteins.
Economics: what it saves and how it charges
UnverifiedPre-revenue biotech: value comes from pipeline drugs and likely partnering; backed by Breyer Capital, Y Combinator, General Catalyst (financing reported at $13M in linked press).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2024 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.